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What’s already known about this topic:21
 Preimplantation genetic diagnosis (PGD) is a reproductive option available to patients22
that are carrier of an autosomal dominant disorder and seeking to have an “unaffected”23
child.24
 The transmission risk where the patient is a mosaic with no family history for the25
disorder can deviate from the mendelian 50% which can lead to confusion at the level of26
diagnosis.27
What’s does this study add:28
 Careful pre-clinical analysis and follow up studies on embryos in some cases of29
autosomal dominant disorders has detected mosaicism for the causative mutation.30
 Knowledge that the patient undergoing PGD for an autosomal dominant disorder with no31
family history is a potential mosaic for the causative mutation will render the diagnosis32
more robust, thereby, reducing the risk of misdiagnosis.33
Ethics statement: PGD for the disorders presented in this study is licenced by the Human34
Fertilisation & Embryology Authority (HFEA). The IVF clinic (Centre for Reproductive and35
Genetic Health) providing the embryonic samples has an HFEA licence to conduct PGD. All36
patient consent forms where obtained for any post PGD/PGD follow-up studies on untransferred37
embryos covered by the HFEA licence. No additional ethical approval was required for this38
study and the authors declare that no ethics was breached.39
Abstract40
Objectives41
Mosaicism in certain dominant disorders may result in a “non-Mendelian” transmission for the42
causative mutation. Preimplantation genetic diagnosis (PGD) is available for patients with43
inherited disorders to achieve an unaffected pregnancy. We present our experience for two44
female patients with different dominantly inherited autosomal disorders; neurofibromatosis type45
1 (NF1) and tuberous sclerosis complex type 2 (TSC2).46
Methods47
PGD protocol development was carried out using single cells from the patients. PGD was carried48
out on polar bodies and different embryonic cells.49
Results50
Protocol development for NF1 using lymphocytes from the patient suggested mosaicism for the51
mutation. This was supported further by quantitative fluorescent-PCR performed on genomic52
DNA. During PGD, polar bodies and blastomeres lacked the mutation that probably was absent53
or present at very low levels in the patient’s germline. Single lymphocyte analysis during54
protocol development for TSC2 did not indicate mosaicism, however, analysis of single buccal55
cells and multiple embryo biopsies across two consecutive IVF/PGD cycles confirmed56
gonosomal mosaicism.57
Conclusions58
The trend in PGD is for blastocyst biopsy followed by whole genome amplification, eliminating59
single cell analysis. In the case of certain dominantly inherited disorders, pre-PGD single cell60
analysis is beneficial to identify potential mosaicism that ensures robust protocols.61
Introduction62
Mosaicism is a condition where an individual has two (or more) genetically distinct cell types.63
Mosaicism may be limited to somal tissues (somatic mosaicism), or the gonads (gonadal64
mosaicism) or present in both (gonosomal mosaicism). The precise timing of post-zygotic65
mutations that occur during development determines the distribution of mutant cells in the66
individual. Mutations that occur before the primordial germ cell (PGC) differentiation, before67
~15 mitotic divisions, can be present in both somatic and germ tissues1. Mutations that occur68
after PGC differentiation will only be present in either the somatic or germline lineages. For69
autosomally inherited disorders an affected individual who has no previous family history has a70
de novo mutation that arose in the individual themselves as a post-zygotic event or in the germ71
cells of a parent of the individual. Depending upon when the de novo mutation occurred, the72
individual will have a transmission risk ranging from 0-50%; therefore careful counselling is73
necessary when considering reproductive options.74
Neurofibromatosis type 1 (OMIM# 162200) is a neurocutaneous disorder with autosomal75
dominant inheritance, complete penetrance and variable expressivity2. It is caused by mutations76
in the NF1 gene located on 17q11.2 and encodes the neurofibromin protein, a negative regulator77
of Ras GTPases3.. The NF1 gene has a very high mutation rate4; approximately 50% of all78
patients with NF1 have no family history of the disease5. A high rate of sporadic mutations79
resulting in mosaic occurrence may explain a milder clinical phenotype known as segmental80
NF16. Germline mosaicism in NF1 has been reported in cases where affected children with a81
characterised mutation were born to healthy parents not showing the mutation in their82
lymphocytes7.83
Tuberous sclerosis complex type 2 (TSC2; OMIM# 191092) is also a neurocutaneous84
multisystem disorder with autosomal dominant inheritance and variable expressivity8. It is85
caused by mutations in TSC2 located on the short arm of chromosome 16 (16p13.3) and encodes86
tuberin9.. Molecular genetic studies have shown that approximately 65% of all patients with87
TSC2 have no family history of the disease10. Mosaicism leading to a variable clinical phenotype88
in TSC2 has been described9 and germline mosaicism has been reported11.89
Preimplantation genetic diagnosis (PGD) is a reproductive option for couples which, unlike90
prenatal diagnosis, allow genetic analysis prior to establishment of a pregnancy13. The couple91
undergoes assisted reproduction so that the embryos are produced by in vitro fertilisation (IVF).92
Embryo biopsy is usually performed at the cleavage stage where 1-2 blastomeres are removed or93
at the blastocyst stage where clumps comprising of 3-5 cells are removed for genetic testing.94
Embryos without the causative mutation are transferred to the uterus so that if a pregnancy95
ensues the fetus is expected to be unaffected for the indication being tested.96
Here we present two cases of PGD where mosaicism for the causative mutation was detected.97
In the first case, mosaicism of an NF1 mutation in a female patient was identified in lymphocytes98
during development of a single-cell PCR protocol prior to PGD. This was supported by analysis99
of polar bodies and blastomeres during PGD.100
In the second case, mosaicism for a mutation in TSC2 was suspected in a female patient during101
the first cycle of PGD on blastomeres. This was confirmed from further analysis of buccal cells102
from the patient, in addition to the analysis of blastomeres, trophectoderm cells and whole103
untransferred embryos of a second cycle of PGD.104
Materials and methods105
Patient description106
NF1107
The patient was a female aged 29 diagnosed with NF1. The referral clinical genetics report108
indicated a heterozygous seven base pair (7bp) duplication in the NF1 gene which caused a109
frameshift in the subsequent coding sequence. No family history of NF1 was reported indicating110
a de novo mutation. Based on a 50% transmission risk of the causative mutation, the patient was111
referred to our centre for PGD.112
TSC2113
The patient was a female aged 31 diagnosed with TSC at the age of 21. The referral genetics114
report indicated that she was heterozygous for a substitution mutation C>T resulting in a stop115
codon and leading to a premature termination of the protein. No family history of TSC2 was116
reported indicating a de novo mutation.117
Genomic DNA extraction, lymphocyte separation and buccal epithelial cell preparation118
Genomic DNA was extracted from peripheral blood collected in tubes containing EDTA from119
the patient couples and female patients’ relatives using the QIAamp DNA Blood Maxi Kit120
(QIAGEN, Manchester, UK).121
Lymphocyte separation was performed on peripheral blood collected in tubes containing lithium122
heparin from the patient couples using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Little123
Chalfont, UK).124
Buccal epithelial cells were collected from the patients with a buccal swab, and resuspended in125
1x PBS (Invitrogen, Paisley, UK).126
Single cell isolation127
Single cell isolation was performed on the separated lymphocytes and buccal epithelial cells128
under an inverted microscope using a 0.2-mm polycarbonate microcapillary (Biohit, Cheshire,129
UK). Single cells were washed three times in 1x PBS drops, which contained 0.1% polyvinyl130
alcohol (Sigma, Dorset, UK). The cells were then transferred to RNase-, DNase-free 0.2-ml PCR131
tubes containing alkaline lysis buffer (50mM dithiothreitol, 200mM NaOH) and stored at -20oC132
until cell lysis at 65oC for 10 min and further amplification.133
Confirmation of mutational status134
DNA from the affected female and her partner for both the NF1 and TSC2 cases were analysed135
by Sanger sequencing to confirm the presence of the reported mutation. DNA from the parents of136
the affected female with NF1 and from one parent and one sibling from the patient with TSC2137
was available. These samples were used to establish the female haplotypes at linked STR138
markers for the NF1 and TSC2 genes respectively.139
PCR protocols and fragment analysis140
The assessment of informativity and haplotyping for linked microsatellite polymorphic markers141
was performed on genomic DNA from the couples and family members using PCR with142
fluorescently labelled primers (Eurogentec, Liège, Belgium). Fragment analysis was performed143
on ABI 3130xl (Life Technologies, Dorset, UK) and the data was analysed using the144
Genemapper analysis software v3.5 (PE Applied Biosystems, Warrington, UK).145
NF1146
Multiplex fluorescent PCR for simultaneous direct mutation detection and linkage analysis was147
carried out using the following: 1) Primers for the mutation locus encompassing the 7bp148
duplication and 2) Linked polymorphic STR markers ivs27AC28.4, D17S1166, NF1int29149
intragenic and centromeric, and D17S1800 0.26Mb telomeric to the 7bp duplication in the NF1150
gene. The detection of a 250bp PCR product at the mutation locus indicated the presence of the151
of the 7bp duplication within the NF1 gene whereas presence of a 243bp fragment identified the152
normal allele.153
TSC2154
Multiplex fluorescent PCR for simultaneous direct mutation detection and linkage analysis was155
carried out using the following 1) Primers for the mutation locus encompassing the C>T156
mutation, 2) Linked polymorphic STR markers D16S3024 0.44Mb telomeric, D16S664 0.26Mb157
and D16S663 0.36Mb centromeric to the C>T mutation. A second round PCR with the mutation158
locus primers and subsequent minisequencing was used to detect the mutant T allele.159
Minisequencing was performed using the SNaPshot® Multiplex Kit (Life Technologies).160
Optimisation of single cell protocols161
To optimise the protocols, single cells were tested under different PCR conditions to achieve an162
amplification efficiency of ≥ 95% and an allele-drop-out (ADO) rate of ≤ 5% at each locus. 163
Efficiency of the marker was defined as the proportion of cells tested that resulted in amplified164
product at the mutation locus. ADO was defined as the proportion of cells known to be165
heterozygous that appeared to be homozygous at a specific locus. This included changing the166
annealing temperature of the protocols and concentration of the primers for the mutation loci. In167
addition, two rounds of PCR were carried out such that the mutation locus was split into a168
singleplex PCR and the remaining STR markers into a quadruplex (in the case of NF1) and169
triplex (in the case of TSC2) for the second round of amplification. The optimised multiplex170
PCR protocol was performed on more than 30 lymphocytes (in the case of NF1) and 50171
lymphocytes (in the case of TSC2) from the female affected partner. Both protocols used the172
QIAGEN Multiplex PCR Kit (QIAGEN) at an annealing temperature of 60oC for 40 cycles.173
Singleplex PCR for the different mutation markers were also performed using the QIAGEN Taq174
PCR Master Mix Kit (QIAGEN).175
Quantitative fluorescent-PCR (QF-PCR)176
Quantitative fluorescent PCR was performed on duplicate genomic DNA samples from the177
patient with NF1 and her partner with the optimised multiplex protocol for a reduced number of178
cycles; 20 and 25. QF-PCR was also performed using a singleplex protocol with the mutation179
primers for the same number of reduced cycles. The QF-PCR was repeated on genomic DNA180
extracted from the peripheral blood of the patient collected seven months after the first sample.181
Quantification was performed after measuring the peak areas of the normalized mutant and182
normal alleles for the mutation locus.183
PGD/IVF treatment184
The IVF treatment was conducted at the Centre for Reproductive and Genetic Health (CRGH).185
The CRGH has a license to conduct PGD from the Human Fertilisation & Embryology Authority186
(HFEA). Both NF1 and TSC2 are disorders licensed by the HFEA. All consent forms were187
obtained from the patients regarding PGD and the use of results/findings in research.188
Following controlled ovarian stimulation human chorionic gonadotropin was administered and189
oocytes were collected transvaginally 37 h later.190
For the NF1 case, oocytes were denuded and the first polar body (PB1) was biopsied and then191
intra-cytoplasmic sperm injection (ICSI) was performed. The second polar body (PB2) was192
biopsied post ICSI. At cleavage stage two blastomeres were removed from each embryo that had193
more than six cells and one blastomere when the embryo had six cells or fewer.194
For the TSC2 case, oocytes were denuded and subjected to ICSI for each of two PGD cycles. A195
cleavage stage biopsy was carried out as described above. A trophectoderm biopsy was also196
performed on all embryos that developed into blastocysts. All untransfered embryos from both197
cycles were collected for follow-up/confirmation analysis.198
All biopsied samples and collected embryos were placed in separate tubes containing alkaline199
lysis buffer. The tubes were stored at -80oC before the cell lysis step and subsequent analysis200
was performed at the UCL Centre for PGD.201
Results202
NF1203
Single-cell multiplex protocol204
To determine the efficiency of diagnosis prior to clinical application, > 30 single lymphocytes205
from the affected female were tested using the optimised multiplex PCR protocol, with the206
acceptance criteria of ≥ 95% for amplification efficiency and ≤ 5% for ADO at each locus. Even 207
after many modifications to the multiplex PCR protocol, we observed an unusually high apparent208
ADO (29%) for the mutation locus only (Table 1). This high apparent drop-out was solely for the209
mutant allele and not the normal one (Figure 1 A, B, C).210
The high apparent ADO was observed for both lymphocyte (Table 1) and buccal epithelial cells211
(data not shown) of the female patient. The ADO rates of all other markers were well within the212
acceptance criteria. In addition, singleplex PCR for the mutation locus on either cell type also213
showed high apparent ADO of the mutant allele for the affected female patient (data not shown).214
Quantitative fluorescent-PCR215
To determine if mosaicism was the cause of the high apparent drop-out observed for the mutant216
allele, QF-PCR was performed. Results obtained from duplicate female genomic DNA samples217
showed that the mean mutant peak area was considerably lower compared to that of the normal218
at two different PCR cycles (mean ratio = 0.46 at 20 cycles and 0.655 at 25 cycles). In addition,219
the allele peak areas of the other heterozygous microsatellite markers present in the multiplex220
were of comparable size (Figure 1 D). The QF-PCR was repeated on genomic DNA extracted221
from the peripheral blood of the patient at another time point with similar results (data not222
shown).223
PGD strategy224
Polar body 1, PB2 and two blastomeres were biopsied sequentially from each embryo This225
approach of multiple biopsies was undertaken to ensure a robust diagnosis in spite of the226
suspected mosaicism for the NF1 mutation in the female patient.227
Embryo diagnosis228
Nineteen embryos (designated 1 to 19) were biopsied and a total of 74 cells were collected. All229
but nine cells (12%) gave results. Seven embryos (3, 4, 7, 8, 9 11 and 17) gave complete results230
from PB1, PB2 and two blastomeres. These embryos were used to determine the parental231
haplotype and deduce the chromosomal segregation at meiosis (Figure 2). Embryo 19 (not232
included in Figure 2) showed external contamination therefore no diagnosis could be reached.233
The mutation was not detected in any of the 63 cells that had successfully amplified and that234
inherited either homologue of maternal chromosome 17.235
The female had an embryo transfer that ensued in a pregnancy and a live birth of an unaffected236
baby. Also, ten embryos that had reached the blastocyst stage were cryopreserved.237
TSC2238
Single-cell multiplex protocol239
With the same acceptance criteria described before for efficiency and ADO, > 50 single240
lymphocytes from the affected female patient were tested using the optimised multiplex PCR241
protocol. All tested markers were within the acceptable ranges except for that of the mutation242
locus which was slightly out of range for ADO (5.9% > 5%) despite many modifications to the243
PCR multiplex protocol and subsequent minisequencing reaction. However, this slightly high244
apparent ADO rate did not alert any suspicion of mosaicism at this pre-clinical single cell245
analysis stage.246
Embryo diagnoses at PGD and follow-up247
Cycle one of PGD248
Six embryos (designated 1 to 6) were biopsied at cleavage stage with a total of 12 blastomeres249
taken and analysed. Figure 3 shows the expected transmission of the parental haplotypes to the250
embryos with the exception of embryo 2 that showed only one paternal chromosome.251
Minisequencing did not detect the mutation in any of the cells from embryos that inherited either252
homologue of maternal chromosome 16. In order to rule out errors due to technical problems, a253
rebiopsy was performed at day 4 post-fertilisation for embryos 1, 3 and 6. Embryo 4 had254
arrested at this stage and the whole embryo was tubed. Analysis was performed on these samples255
and minisequencing confirmed the results obtained before. Embryo 5 was a hatching blastocyst256
on day 6 that was rebiopsied and cryopreserved. The remaining whole embryos (1, 3 and 6)257
which had arrested and the trophectoderm biopsy from Embryo 5 were analysed by both258
minisequencing and Sanger sequencing. The results reconfirmed the diagnosis obtained from259
previous analyses. Figure 3 shows the sequential mutation detection results obtained for embryo260
4 as compared to the patient couple.261
The optimised PGD protocol was then performed on buccal epithelial cells isolated from the262
female patient. A high apparent ADO rate (12.5%) was observed for the mutant allele hinting263
that the female patient might be mosaic for the mutation in her buccal epithelial cell lineage.264
Cycle two of PGD265
The patient was counselled and opted for a second cycle of PGD. Five embryos (designated 1 to266
5) were biopsied at cleavage stage with a total of nine blastomeres taken and analysed. Figure 3267
shows the transmission of the parental haplotypes to the embryos with the exception of embryo 5268
that showed only one paternal chromosome. Minisequencing detected the presence of the mutant269
allele T in Embryo 3, but not in Embryo 4, which had the same haplotype at the linked markers270
indicating that the female patient was mosaic in her germline for the TSC2 mutation. This finding271
of germline/gonadal mosaicism was supported by the resultsobtained from the first cycle of272
PGD where the mutation was not detected in any of the embryonic samples having inherited273
either maternal haplotype. Having detected both somatic (buccal cells) and germline mosaicism274
we suggest that the female patient had gonosomal mosaicism for the mutation. Embryo 2 from275
the second cycle was transferred because it did not have the mutation and also had the other276
maternal homologue of chromosome 16 compared to embryo 3. The remaining untransferred277
embryos were reanalysed by both minisequencing and Sanger sequencing confirming the results278
obtained in PGD (data not shown).279
Discussion280
For the NF1 case, the single cell analysis of lymphocytes performed prior to PGD indicated that281
the female patient was mosaic for the mutation at least in her lymphoblastic lineage. This was282
supported by QF-PCR performed on her genomic DNA where there was a decrease in the peak283
area for the mutant allele compared to the normal one. Results from all PBs and embryos did not284
detect the mutation identified in lymphocytes from the patient indicating that her germline is285
either mosaic or lacking the mutation.286
For the TSC2 case, the single cell analysis performed prior to PGD using lymphocytes did not287
show a clear indication of mosaicism for the mutation. PGD in the first cycle showed absence of288
the mutation in spite of each maternal homologue of chromosome 16 being separately289
represented in the embryos. Testing of buccal epithelial single cells showed a high apparent290
ADO rate (12.5%) for the mutation and the analyses of untransfered embryos obtained from291
cycle one and two altogether indicated gonosomal mosacism in this individual.292
Both NF1 and TSC are frequent autosomal dominant disorders. Up to 50% of patients with NF15-293
6 and 65 % of patients with TSC10 have de novo mutations with no family history for the disease.294
This can result in germline mosaicism resulting in < 50% transmission risk, which is a major295
consideration that should be taken into account in diagnostic settings such as PGD. Clinically, it296
can be difficult to identify mosaicism for a mutation especially in the case of genetic diseases297
with variable expressivity.298
Here we report mosaicism for a mutation in two disorders that are commonly considered for299
PGD. Somatic mosaicism was identified in one situation (NF1) through routine single cell300
analysis conducted prior to PGD. This led to analysis of PBs and blastomeres in the clinical301
cycle to ensure that the protocol was sufficiently robust to give a conclusive diagnosis when302
there was evidence of mosaicism. In another situation (TSC2), both somatic and germline303
mosaicism for the causative mutation was identified through extensive embryo analysis and304
follow-up studies, which enabled appropriate counselling of the patient prior to embryo transfer.305
PGD for dominantly inherited disorders where there is no family history relies on detection of306
the mutation in embryos. Once the phase of the mutation is established with the haplotype at307
linked markers the diagnosis is not only dependent on the mutation locus alone. When308
mosaicism is identified in somatic tissues, testing of many single sperm will identify germline309
mosaicism in males. In females however it is not possible to predict whether there is mosaicism310
or if the mutation is present in the germline.311
Recently the blastocyst has become the preferred stage of biopsy although fewer embryos reach312
this stage of development14. ADO is low in trophectoderm samples derived from a blastocyst313
biopsy and single cell analysis prior to PGD is minimal with no protocol optimisation. In spite of314
the lower ADO rate in trophectoderm samples a conclusive diagnosis may be difficult in de novo315
cases when there are few embryos and it is uncertain if germline mosaicism for the causative316
mutation is present. For this reason and for cases of autosomal dominant disorders that show317
mosaicism, single cell analysis prior to PGD should include the cells of different lineages to318
identify mosaicism in order to minimise inconclusive results at PGD. Making a diagnosis using319
independent tests such as polar body analysis together with blastomere or trophectoderm analysis320
reduces the risk of misdiagnosis in these cases.321
322
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Captions to table and figures379
380
Table 1. Results of the optimised pre-PGD single cell PCR tests of the female patient with NF1381
showing an unusually high level of apparent ADO (29%) for the NF1 mutation locus. The382
apparent drop-out at the mutation locus was only for the mutant allele and not the normal one.383
The patient was not heterozygous at the D17S1166 locus and thus % ADO was not applicable384
(N/A).385
Figure 1. Electropherograms of the optimised multiplex PCR protocol performed on single386
lymphocytes (A, B, C) and QF-PCR at 20 cycles performed on genomic DNA (D) from the387
patient couple. (A) Lymphocyte from the affected female showing both mutant and normal388
alleles. (B) Lymphocyte from the affected female showing an apparent drop-out of the mutant389
allele. (C) Lymphocyte from the male partner showing only the normal allele. (D) A decrease in390
the mutant allele peak area relative to the normal one for the NF1 mutation locus is observed; for391
comparison, the peak areas of both alleles for STR marker D17S1800 are shown to be of similar392
size.393
Figure 2. The transmission of the parental haplotypes on chromosome 17 to the embryos based394
on results obtained for the linked STR polymorphic markers IVS27AC28.4, D17S1166,395
NF1int29 centromeric and D17S1800 telomeric to the mutation locus. The mutant NF1 allele396
(250bp) was not detected in any of the biopsied cells. Embryos were colour-coded and the397
proposed segregation results are shown. Embryos 1, 2 and 15 showed homologous398
recombination in meiosis 1. There was a non-disjunction event at meiosis II for Embryo 5,399
whereas, for Embryo 14 premature segregation of sister chromatids in meiosis I may have400
occurred. Errors in meiosis I or II appear to have occurred in embryos 10 and 16. resulting in a401
possible trisomy of chromosome 17 in embryo 16. Each of the two blastomeres from embryo 12402
showed a different and only one parental haplotype suggestive of ‘embryonic mosaicism’ for403
chromosome 17. E: embryo, PB1: polar body 1, PB2: polar body 2, B: blastomere, NR: no result,404
ADO: allele-drop-out.405
Figure 3. The transmission of the parental haplotypes on chromosome 16 to the embryos for406
PGD cycles one and two of the patient couple with TSC2. This was based on results obtained for407
the linked STR polymorphic markers D16S3024 telomeric and D16S664, D16S663 centromeric408
to the TSC2 C>T mutation. Compared to the affected female and normal male partners, the409
mutant T allele was not detected in any of the biopsied cells in cycle one of PGD when analysed410
by Sanger sequencing and minisequencing (left and right electropherograms respectively),411
shown here only for embryo 4. Minisequencing in cycle two of PGD detected the mutant T allele412
in embryo 3, which was used to establish the phase with the linked STR markers. SS: Sanger413
sequencing, MS: minisequencing, E: embryo, B: blastomere.414
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IVS27AC28.4 D17S1166 NF1int29
Mutation
locus D17S1800
Efficiency (%) 32/32 (100) 32/32 (100) 32/32 (100) 31/32 (97) 32/32 (100)
Apparent ADO
(%) 1/32 (3) N/A 0/32 (0) 9/31 (29) 0/32 (0)
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